The AUH Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human A-549 lung adenocarcinoma cell line. This product provides a heterogeneous pool of cells with targeted disruption of the AUH gene, enabling loss-of-function studies in a cancer-relevant epithelial background. The polyclonal format preserves diverse genomic editing outcomes across the population, facilitating the study of gene function without clonal selection biases.
The parental A-549 cell line was originally isolated from a 58-year-old Caucasian male with lung adenocarcinoma and exhibits an adherent epithelial morphology. Widely employed in biomedical research, A-549 cells serve as a well-characterized model for respiratory virus infection, cancer biology, and drug screening. Their retention of key signal transduction pathways and metabolic features of lung adenocarcinoma makes them a robust platform for investigating oncogenic mechanisms and therapeutic vulnerabilities.
The AUH gene encodes a bifunctional protein that integrates RNA regulation with mitochondrial leucine catabolism. It binds AU-rich elements (AREs) in the 3?? untranslated regions of target mRNAs, modulating stability and translation of transcripts such as TNF-??, IL-2, and c-Fos. Concurrently, AUH functions as a methylglutaconyl-CoA hydratase in the leucine degradation pathway, converting methylglutaconyl-CoA to 3-hydroxy-3-methylglutaconyl-CoA. AUH interacts with HNRNPD (AUF1) and ELAVL1 (HuR) to mediate ARE-dependent decay, while its metabolic activity involves components like HMGCL and HMGCS2. Upstream, PGC-1?? (PPARGC1A) is implicated in regulating mitochondrial functions that may influence AUH expression, though direct transcriptional control remains to be fully elucidated.
Disruption of AUH in A-549 cells creates a valuable model for dissecting the dual roles of this protein in cancer and metabolism. Loss of AUH is predicted to impair leucine catabolism, potentially leading to accumulation of intermediates linked to 3-methylglutaconic aciduria type I, a condition associated with neurodevelopmental disorders. In the lung adenocarcinoma context, abrogation of AUH??s RNA-binding function may alter ARE-mediated post-transcriptional regulation of oncogenic and inflammatory genes, impacting cell proliferation, apoptosis, and response to microenvironmental cues. This polyclonal knockout approach allows researchers to capture a spectrum of phenotypic consequences, from metabolic shifts to changes in mRNA stability.
This knockout model supports a broad range of experimental workflows. Investigators can employ Western blotting to confirm AUH protein loss and enzyme activity assays to evaluate hydratase function. Transcriptomic analyses via qPCR or RNA-seq enable monitoring of ARE-containing mRNA stability changes, while LC-MS-based metabolic profiling detects perturbations in organic acid levels. Functional assays such as cell proliferation, apoptosis, and drug sensitivity testing facilitate cancer biology and drug metabolism studies, including respiratory viral infection research. The polyclonal pool is particularly suited for screening applications where heterogeneous gene editing provides a realistic representation of target inhibition. For technical inquiries, please contact Ascent Research.
